Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-06-17

Study of immunogenicity of DNA HIV-1 env, gag and pol plasmid vaccines boosted with MVA in Tanzania; HIV vaccine immunogenicity study

Objective

HIV-l vaccines are urgently needed especially in developing nations. HIV vaccine study sites are needed in developing nations for more rapid development and deployment of vaccines. DNA plasmid vaccines are promising candidates - Their potency needs to be improved. The programme will explore various modes of increasing the immunogenicity of priming with plasmid DNA; intradermal injections, with GM-CSF as adjuvant, intramucosal injections and boosting with a Modified Vaccinia Ankara vector, MVA. Vaccines produced from subtypes appropriate for Tanzania will be used. A study site will be established in Dar es Salaam- The prerequisites for approval will be addressed on all levels, paving the way to future trials - Immunogenicity studies will continue in Dar es Salaam, with a focus on mucosal immunity and durability of the immune response.

Call for proposal

Data not available

Coordinator

KAROLINSKA INSTITUTE
EU contribution
No data
Address
Ringwaegen, 52
11883 STOCKHOLM
Sweden

See on map

Total cost
No data

Participants (4)